Treatment Outcomes and Estimated Costs Associated with BCG Therapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer – Expert Commentary

Non-muscle invasive bladder cancers (NMIBC) constitute the majority of bladder cancer diagnoses. NMIBCs are stratified based on the risk of progression to muscle-invasive disease into low, intermediate, and high-risk groups. NMIBC has the highest lifetime treatment costs of all cancers in the USA.